ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 219 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q3 2023. The put-call ratio across all filers is 0.74 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,896 | -36.2% | 53,193 | -17.5% | 0.00% | -25.0% |
| Q2 2023 | $2,973 | +19.0% | 64,446 | +3.4% | 0.00% | +33.3% |
| Q1 2023 | $2,499 | -22.5% | 62,329 | -10.4% | 0.00% | -25.0% |
| Q4 2022 | $3,225 | -99.9% | 69,600 | -43.9% | 0.00% | -42.9% |
| Q3 2022 | $5,135,000 | -50.7% | 123,995 | -29.0% | 0.01% | -50.0% |
| Q2 2022 | $10,418,000 | -22.5% | 174,630 | -5.6% | 0.01% | 0.0% |
| Q1 2022 | $13,438,000 | -12.9% | 185,040 | +0.9% | 0.01% | -6.7% |
| Q4 2021 | $15,422,000 | -10.7% | 183,403 | -4.2% | 0.02% | -16.7% |
| Q3 2021 | $17,267,000 | -3.5% | 191,446 | +2.0% | 0.02% | -5.3% |
| Q2 2021 | $17,898,000 | -0.5% | 187,705 | +18.9% | 0.02% | -5.0% |
| Q1 2021 | $17,979,000 | -12.1% | 157,906 | +6.8% | 0.02% | -13.0% |
| Q4 2020 | $20,461,000 | +90.1% | 147,806 | +12.8% | 0.02% | +76.9% |
| Q3 2020 | $10,766,000 | +7.6% | 130,994 | +2.4% | 0.01% | 0.0% |
| Q2 2020 | $10,004,000 | +355.8% | 127,894 | +158.9% | 0.01% | +333.3% |
| Q1 2020 | $2,195,000 | +4.7% | 49,400 | +0.6% | 0.00% | +50.0% |
| Q4 2019 | $2,097,000 | -14.8% | 49,100 | -14.6% | 0.00% | -33.3% |
| Q3 2019 | $2,460,000 | -30.8% | 57,500 | +2.7% | 0.00% | -25.0% |
| Q2 2019 | $3,556,000 | -3.1% | 56,000 | +5.9% | 0.00% | -20.0% |
| Q1 2019 | $3,669,000 | +83.1% | 52,900 | +14.8% | 0.01% | +66.7% |
| Q4 2018 | $2,004,000 | -51.0% | 46,100 | -14.0% | 0.00% | -40.0% |
| Q3 2018 | $4,092,000 | +1.8% | 53,600 | +2.5% | 0.01% | 0.0% |
| Q2 2018 | $4,020,000 | +65.0% | 52,300 | +9.4% | 0.01% | +66.7% |
| Q1 2018 | $2,437,000 | +21.6% | 47,800 | +10.6% | 0.00% | +50.0% |
| Q4 2017 | $2,004,000 | -46.3% | 43,200 | -38.3% | 0.00% | -60.0% |
| Q3 2017 | $3,730,000 | -14.3% | 70,036 | 0.0% | 0.01% | -16.7% |
| Q2 2017 | $4,350,000 | -1.3% | 70,036 | +7.7% | 0.01% | 0.0% |
| Q1 2017 | $4,409,000 | +1.9% | 65,049 | +5.7% | 0.01% | 0.0% |
| Q4 2016 | $4,327,000 | -0.9% | 61,548 | 0.0% | 0.01% | 0.0% |
| Q3 2016 | $4,366,000 | +45.0% | 61,548 | 0.0% | 0.01% | +50.0% |
| Q2 2016 | $3,010,000 | -28.9% | 61,548 | -8.0% | 0.00% | -33.3% |
| Q1 2016 | $4,236,000 | -33.6% | 66,901 | +17.6% | 0.01% | -40.0% |
| Q4 2015 | $6,380,000 | +33.4% | 56,877 | +14.6% | 0.01% | +25.0% |
| Q3 2015 | $4,781,000 | +82.3% | 49,637 | +93.8% | 0.01% | +100.0% |
| Q2 2015 | $2,622,000 | +1131.0% | 25,610 | +580.2% | 0.00% | – |
| Q3 2014 | $213,000 | – | 3,765 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| GREAT POINT PARTNERS LLC | 727,426 | $25,932,737 | 4.72% |
| RTW INVESTMENTS, LP | 5,405,089 | $192,691,423 | 4.07% |
| First Light Asset Management, LLC | 1,125,032 | $40,107,391 | 3.81% |
| CHI Advisors LLC | 215,000 | $7,664,750 | 3.04% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 250,052 | $8,914,354 | 3.00% |
| SPHERA FUNDS MANAGEMENT LTD. | 259,135 | $9,238,163 | 1.68% |
| Rock Springs Capital Management LP | 1,476,441 | $52,635,122 | 1.41% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 679,459 | $24,222,713 | 1.31% |
| Privium Fund Management B.V. | 115,241 | $4,108,341 | 1.22% |
| SECTOR GAMMA AS | 115,166 | $4,105,668 | 1.05% |